Citigroup
DNTH icon

Citigroup’s Dianthus Therapeutics DNTH Stock Holding History

Citigroup’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$645K Sell
7,685
-3,407
-31% -$197K ﹤0.01% 3391
2025
Q4 		$457K Sell
11,092
-57,387
-84% -$2.22M ﹤0.01% 3617
2025
Q3 		$2.69M Buy
68,479
+56,809
+487% +$1.45M ﹤0.01% 2420
2025
Q2 		$217K Sell
11,670
-23,150
-66% -$434K ﹤0.01% 4024
2025
Q1 		$632K Buy
34,820
+4,278
+14% +$94.3K ﹤0.01% 3549
2024
Q4 		$666K Buy
30,542
+13,148
+76% +$338K ﹤0.01% 3630
2024
Q3 		$476K Buy
17,394
+11,309
+186% +$315K ﹤0.01% 3761
2024
Q2 		$157K Sell
6,085
-16,651
-73% -$400K ﹤0.01% 4005
2024
Q1 		$682K Buy
22,736
+5,329
+31% +$116K ﹤0.01% 3331
2023
Q4 		$181K Buy
17,407
+13,539
+350% +$150K ﹤0.01% 3952
2023
Q3 		$52.9K Buy
+3,868
New +$48.7K ﹤0.01% 4113
2023
Q1 		– Sell
-46
Closed -$291 – 5583
2022
Q4 		$291 Buy
46
+2
+5% +$35 ﹤0.01% 5563
2022
Q3 		$1K Sell
44
-30
-41% -$821 ﹤0.01% 5621
2022
Q2 		$1K Sell
74
-74
-50% -$1.83K ﹤0.01% 6008
2022
Q1 		$7K Sell
148
-439
-75% -$24K ﹤0.01% 5679
2021
Q4 		$42K Buy
587
+186
+46% +$18.7K ﹤0.01% 5144
2021
Q3 		$47K Buy
401
+91
+29% +$10.6K ﹤0.01% 4762
2021
Q2 		$48K Buy
310
+89
+40% +$16.3K ﹤0.01% 4843
2021
Q1 		$42K Sell
221
-193
-47% -$32.5K ﹤0.01% 4793
2020
Q4 		$52K Buy
414
+97
+31% +$11K ﹤0.01% 6013
2020
Q3 		$34K Buy
317
+23
+8% +$2.73K ﹤0.01% 5843
2020
Q2 		$35K Sell
294
-282
-49% -$39.7K ﹤0.01% 6225
2020
Q1 		$58K Buy
576
+146
+34% +$27.1K ﹤0.01% 5843
2019
Q4 		$104K Buy
430
+307
+250% +$57.4K ﹤0.01% 5743
2019
Q3 		$20K Sell
123
-274
-69% -$52.1K ﹤0.01% 6733
2019
Q2 		$94K Buy
397
+127
+47% +$31.4K ﹤0.01% 5933
2019
Q1 		$71K Buy
270
+243
+900% +$41.9K ﹤0.01% 6053
2018
Q4 		$2K Sell
27
-44
-62% -$6K ﹤0.01% 7501
2018
Q3 		$14K Buy
+71
New +$14.9K ﹤0.01% 7235

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup's DNTH Position: Q1 2026 in Review

Citigroup reduced its Dianthus Therapeutics (DNTH) stake by 31% in Q1 2026, selling an estimated $197K and leaving 7,685 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #3391.

Citigroup first reported a position in DNTH in Q3 2018 and has held it in 29 quarters since. The position peaked at $2.69M in Q3 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Citigroup held 7,685 shares of Dianthus Therapeutics worth $645K as of Q1 2026.
  • Citigroup sold 3,407 Dianthus Therapeutics shares in Q1 2026, an estimated $197K.
  • Dianthus Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3391 holding.
  • Citigroup first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • Citigroup's Dianthus Therapeutics position peaked at $2.69M in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.